NCT05068102 2026-04-20
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
Boehringer Ingelheim
Phase 1 Active not recruiting
Clinical Trials
21 trialsNCT05172245 2026-04-17
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT04533750 2026-04-13
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT07156227 2026-04-13
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT06868433 2026-03-04
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Emory University
Phase 1 Recruiting
NCT04752215 2026-02-02
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
Boehringer Ingelheim
Phase 1 Completed
NCT04603287 2025-09-26
A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Active not recruiting
NCT04576091 2024-12-13
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04870840 2024-10-29
Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT06307093 2024-03-12
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms
R-Pharm
Phase 1 Unknown
NCT02437916 2022-11-08
Safety Study of AMG 228 to Treat Solid Tumors
Amgen
Phase 1 Terminated
NCT04596033 2022-07-15
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Genocea Biosciences, Inc.
Phase 1 Terminated
NCT02636036 2021-11-09
SPICE
Akamis Bio
Phase 1 Completed
NCT01353625 2021-10-05
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
Celgene
Phase 1 Completed
NCT02277184 2017-11-13
Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
University of Pittsburgh
Phase 1 Terminated
NCT02211027 2017-09-07
Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA
University of Pittsburgh
Phase 1 Withdrawn
NCT00513383 2017-03-01
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
Massachusetts General Hospital
Phase 1 Completed
NCT00377247 2016-07-11
Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor
University of Pittsburgh
Phase 1 Terminated
NCT00243347 2013-10-17
The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer
AstraZeneca
Phase 1 Completed
NCT00078546 2012-07-30
CLANC
Baylor College of Medicine
Phase 1 Completed
NCT00396617 2012-07-02
Voice Prosthesis Made in Porous Titanium After Total Laryngectomy or Pharyngolaryngectomy
University Hospital, Strasbourg, France
Phase 1 Unknown